Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | PRKCA | P17252 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.30 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.30 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.30 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.30 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12305438 | 0.85 | MMP8 (0.37) | SMN1; SMN2MMP8TSHRALDH1A1PRKCA | |
| SCHEMBL4763733 | 0.80 | TSHR (0.41) | SMN1; SMN2MMP8TSHRALDH1A1PRKCA | |
| SCHEMBL18430092 | 0.79 | PKM (0.43) | MMP8TSHRALDH1A1KDM4EMAPT | |
| SCHEMBL23812618 | 0.79 | TSHR (0.38) | SMN1; SMN2MMP8TSHRALDH1A1PRKCA | |
| SCHEMBL12761590 | 0.78 | TSHR (0.39) | SMN1; SMN2MMP8TSHRALDH1A1PRKCA | |
| SCHEMBL18924771 | 0.78 | TSHR (0.39) | SMN1; SMN2MMP8TSHRALDH1A1PRKCA | |
| SCHEMBL12310627 | 0.78 | SMN1; SMN2 (0.45) | SMN1; SMN2MMP8TSHRALDH1A1PRKCA | |
| SCHEMBL23065599 | 0.78 | HCAR2 (0.36) | SMN1; SMN2TSHRALDH1A1KDM4EMAPK1 | |
| SCHEMBL19591877 | 0.76 | TSHR (0.36) | SMN1; SMN2MMP8TSHRMAPTMAPK1 | |
| SCHEMBL685935 | 0.74 | PRKCA (0.55) | SMN1; SMN2MMP8TSHRALDH1A1PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210061806-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2021-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061806-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | SMN1; SMN2 746/4885MMP8 2057/4885TSHR 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.